Figure 2
ctDNA dynamics of type I and II patients.
Vertical axis, PM score for EGFR mutations (left) or protein concentration (μg/mL) for CEA (right). Horizontal axis, days from initiation of EGFR-TKI. Horizontal lines at the top of each panel indicate treatment, vertical bars indicate initiation of therapy and arrowheads indicate termination of therapy. Gray arrows below the horizontal lines indicate radiotherapy. Black arrowheads in the bottom of each panel indicate PD points. White arrowheads in each panel indicate IP points. Blue lines indicate activating mutations (exon 19 deletion or L858R). Red lines indicate T790M. Black broken lines indicate CEA. For patients who had no data exceeding LOD (PM score) or whose data were within the normal range (CEA), data were not presented in graphs. (a) Patient 1 (type I). (b) Patient 5 (type I). (c) Patient 11 (type I). (d) Patient 12 (type II). (e) Patient 13 (type II). (f) Patient 14 (type II). Abbreviations are as follows: CDDP, cisplatin; PEM, pemetrexed; CBDCA, carboplatin; nabPTX, nab-paclitaxel; PTX, paclitaxel; BEV, bevacizumab.
